Exelixis Inc
$ 43.92
2.86%
13 Feb - close price
- Market Cap 11,448,390,000 USD
- Current Price $ 43.92
- High / Low $ 44.05 / 42.73
- Stock P/E 15.47
- Book Value 8.23
- EPS 2.76
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 0.36 %
- 52 Week High 49.62
- 52 Week Low 32.38
About
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.
Analyst Target Price
$47.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-10-27 | 2025-07-28 | 2025-04-28 | 2025-02-04 | 2024-10-29 | 2024-08-06 | 2024-04-30 | 2024-02-06 | 2023-11-01 | 2023-08-01 | 2023-05-09 |
| Reported EPS | 0.94 | 0.78 | 0.65 | 0.62 | 0.55 | 0.4 | 0.77 | 0.2 | 0.27 | 0.1 | 0.25 | 0.12 |
| Estimated EPS | 0.8031 | 0.6931 | 0.64 | 0.3666 | 0.4918 | 0.35 | 0.3 | 0.24 | 0.21 | 0.1 | 0.16 | 0.15 |
| Surprise | 0.1369 | 0.0869 | 0.01 | 0.2534 | 0.0582 | 0.05 | 0.47 | -0.04 | 0.06 | 0 | 0.09 | -0.03 |
| Surprise Percentage | 17.0464% | 12.5379% | 1.5625% | 69.1217% | 11.8341% | 14.2857% | 156.6667% | -16.6667% | 28.5714% | 0% | 56.25% | -20% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.7442 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EXEL
2026-02-13 08:58:36
Assetmark Inc. significantly increased its stake in Exelixis, Inc. ($EXEL) by over 1,200% in Q3, now holding 3.19 million shares valued at $131.99 million. The biotechnology company recently beat Q4 EPS expectations but missed on revenue, while preparing for a potential 2026 launch of its colorectal cancer drug, zanzalintinib. Analyst sentiment is mixed, with an average price target of $47.11, reflecting both confidence in the pipeline and near-term uncertainties from conservative revenue guidance.
2026-02-13 02:58:36
H.C. Wainwright increased its price target for Exelixis (NASDAQ:EXEL) to $54 from $52, maintaining a Buy rating after the biopharmaceutical company reported better-than-expected Q4 2025 diluted net income of $0.88 per share. This positive adjustment is supported by InvestingPro data indicating the stock is trading below its Fair Value with a low PEG ratio. The firm also projected an increase in full-year 2026 net earnings to $3.15 per share, citing the company's strong cash position.
2026-02-12 13:44:38
LSV Asset Management reduced its stake in Exelixis, Inc. by 0.7% in the third quarter, holding 7,768,627 shares worth $320,844,000. Other hedge funds also made minor adjustments to their holdings. Exelixis reported strong quarterly earnings, beating analyst estimates, and analysts have mixed ratings on the stock with a consensus "Hold" and a target price of $47.11.
2026-02-12 13:27:41
H.C. Wainwright has increased its price target for Exelixis (NASDAQ:EXEL) to $54 from $52, maintaining a Buy rating, following the biopharmaceutical company's strong fourth-quarter 2025 earnings. Exelixis reported diluted net income of $0.88 per share, surpassing forecasts, and generated $598.7 million in total revenue. The firm also adjusted its full-year 2026 net earnings projection for Exelixis upwards and noted the company's substantial cash reserves.
2026-02-12 01:58:19
Exelixis detailed its growth strategy, highlighted by the strong performance of its CABOMETYX franchise, which generated $2.12 billion in revenue. The company is actively preparing for the potential launch of zanzalintinib in 2026, a key component of its future pipeline. This strategy focuses on leveraging existing successes while expanding into new therapeutic areas with novel compounds.
2026-02-11 12:57:45
Exelixis, Inc. reported strong Q4 and full-year 2025 financial results, with US cabozantinib franchise net product revenues growing 17% to $2.12 billion for the full year. The company is advancing zanzalintinib as its next oncology franchise, with an NDA accepted for the ZanzaAteza combination in third-line plus colorectal cancer and seven ongoing pivotal trials. Exelixis aims to build a multi-franchise business in solid tumor oncology, focusing on expanding its leadership in GI indications while continuing to grow its cabozantinib business in GU oncology.
